198 related articles for article (PubMed ID: 33076776)
61. Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration.
Patel SS; Goldfarb M
J Surg Oncol; 2013 May; 107(6):665-72. PubMed ID: 23192391
[TBL] [Abstract][Full Text] [Related]
62. Low iodine diet in differentiated thyroid cancer: a review.
Li JH; He ZH; Bansal V; Hennessey JV
Clin Endocrinol (Oxf); 2016 Jan; 84(1):3-12. PubMed ID: 26118628
[TBL] [Abstract][Full Text] [Related]
63. Use of fractionated doses of iodine-131 for ablation of thyroid remnants.
Wang SJ; Liu TJ
Zhonghua Yi Xue Za Zhi (Taipei); 2002 Jul; 65(7):336-40. PubMed ID: 12365652
[TBL] [Abstract][Full Text] [Related]
64. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective.
Mernagh P; Campbell S; Dietlein M; Luster M; Mazzaferri E; Weston AR
Eur J Endocrinol; 2006 Sep; 155(3):405-14. PubMed ID: 16914594
[TBL] [Abstract][Full Text] [Related]
65. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
[TBL] [Abstract][Full Text] [Related]
66. Recombinant human thyrotropin in thyroid remnant ablation with 131-iodine in high-risk patients.
Rosario PW; Xavier AC; Calsolari MR
Thyroid; 2010 Nov; 20(11):1247-52. PubMed ID: 20950256
[TBL] [Abstract][Full Text] [Related]
67. Post-surgical ablation of thyroid residues with radioiodine in Ukrainian children and adolescents affected by post-Chernobyl differentiated thyroid cancer.
Oliynyk V; Epshtein O; Sovenko T; Tronko M; Elisei R; Pacini F; Pinchera A
J Endocrinol Invest; 2001 Jun; 24(6):445-7. PubMed ID: 11434669
[TBL] [Abstract][Full Text] [Related]
68. Initial staging of differentiated thyroid carcinoma: continued utility of posttherapy 131I whole-body scintigraphy.
Donahue KP; Shah NP; Lee SL; Oates ME
Radiology; 2008 Mar; 246(3):887-94. PubMed ID: 18309016
[TBL] [Abstract][Full Text] [Related]
69. Management of thyroid cancer: radioiodine ablation, "stunning," and treatment of thyroglobulin-positive, (131)I scan-negative patients.
Hurley JR
Endocr Pract; 2000; 6(5):401-6. PubMed ID: 11141594
[TBL] [Abstract][Full Text] [Related]
70. Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine.
Kluijfhout WP; Pasternak JD; Drake FT; Beninato T; Shen WT; Gosnell JE; Suh I; C L; Duh QY
Surgery; 2017 Jan; 161(1):127-133. PubMed ID: 27855968
[TBL] [Abstract][Full Text] [Related]
71. Management of thyroid carcinoma with radioactive 131I.
Paryani SB; Chobe RJ; Scott W; Wells J; Johnson D; Kuruvilla A; Schoeppel S; Deshmukh A; Miller R; Dajani L; Montgomery CT; Puestow E; Purcell J; Roura M; Sutton D; Mallett R; Peer J
Int J Radiat Oncol Biol Phys; 1996 Aug; 36(1):83-6. PubMed ID: 8823262
[TBL] [Abstract][Full Text] [Related]
72. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
[TBL] [Abstract][Full Text] [Related]
73. Comparable Ablation Efficiency of 30 and 100 mCi of I-131 for Low to Intermediate Risk Thyroid Cancers Using Triple Negative Criteria.
Fatima N; Zaman MU; Zaman A; Zaman U; Tahseen R
Asian Pac J Cancer Prev; 2016; 17(3):1115-8. PubMed ID: 27039734
[TBL] [Abstract][Full Text] [Related]
74. Effects of Radioactive Iodine Ablation Therapy on Voice Quality.
Aydoğdu İ; Atar Y; Saltürk Z; Sarı H; Ataç E; Aydoğdu Z; İnan M; Mersinlioğlu G; Uyar Y
J Voice; 2017 Jan; 31(1):94-96. PubMed ID: 27377232
[TBL] [Abstract][Full Text] [Related]
75. Treatment options for Graves disease: a cost-effectiveness analysis.
In H; Pearce EN; Wong AK; Burgess JF; McAneny DB; Rosen JE
J Am Coll Surg; 2009 Aug; 209(2):170-179.e1-2. PubMed ID: 19632593
[TBL] [Abstract][Full Text] [Related]
76. Radioactive Iodine in Differentiated Carcinoma of Thyroid: An Overview.
Singh NK; Ramamourthy B; Hage N; Nagaraju S; Kappagantu KM
Curr Radiopharm; 2024; 17(1):2-6. PubMed ID: 37877561
[TBL] [Abstract][Full Text] [Related]
77. Radioactive iodine therapy.
Lee SL
Curr Opin Endocrinol Diabetes Obes; 2012 Oct; 19(5):420-8. PubMed ID: 22914564
[TBL] [Abstract][Full Text] [Related]
78. Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review.
Blumhardt R; Wolin EA; Phillips WT; Salman UA; Walker RC; Stack BC; Metter D
Endocr Relat Cancer; 2014; 21(6):R473-84. PubMed ID: 25277792
[TBL] [Abstract][Full Text] [Related]
79. Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma.
Prpic M; Kruljac I; Kust D; Kirigin LS; Jukic T; Dabelic N; Bolanca A; Kusic Z
Endocrine; 2016 Jun; 52(3):602-8. PubMed ID: 26732041
[TBL] [Abstract][Full Text] [Related]
80. Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome.
Logue JP; Tsang RW; Brierley JD; Simpson WJ
Br J Radiol; 1994 Nov; 67(803):1127-31. PubMed ID: 7820407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
